In 2023, Vertex earned approval for Casgevy, a gene-editing treatment for two rare blood-related conditions with very few treatment options. Vertex Pharmaceuticals didn't create Casgevy itself ...

The company is also making progress with Casgevy, its gene therapy treatment. While the launch is in its early stages, with over 50 treatment centers activated globally and more than 50 patients ...

Secondly, McKesson’s dedicated business unit, InspiroGene, partnered with Vertex Pharmaceuticals to expand distribution options for CASGEVY, the first CRISPR-based gene-editing therapy approved ...

Vertex and partner CRISPR Therapeutics’ CRSP one-shot gene therapy Casgevy was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in ...

I recently had my first blood transfusion of the year. It’s one of the most common treatments for sickle cell disease. I must undergo cross-match testing no more than 72 hours before my scheduled ...

For example, the FDA-approved CRISPR-Cas9-based therapy Casgevy, designed to treat sickle cell disease, provides life-changing potential but comes at a staggering one-time cost of $2.2 million.

The company's flagship product, Casgevy, developed in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX), has garnered significant attention as it represents one of the first gene-edited ...